Article
TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.
Breast cancer research and treatment - 1 Feb 2012
Hertel Pernille Braemer, Tu Dongsheng, Ejlertsen Bent, Jensen Maj-Britt, Balslev Eva, Jiang Shan, O'Malley Frances P, Pritchard Kathleen I, Shepherd Lois E, Bartels Annette, Brünner Nils, Nielsen Torsten O
Abstract excerpt
HER2 amplification, TOP2A aberrations, and absence of tissue inhibitor of metalloproteinase (TIMP-1) expression in breast carcinomas have been shown to be associated with incremental benefit from anthracycline-containing adjuvant chemotherapy, and this study was undertaken to validate these findings in a similar, but independent, randomized clinical trial. TIMP-1 was examined by immunohistochemistry in archival...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.